Scroll Top

Newly FDA Approved Device to Treat Urinary and Bowel Dysfunction Now Available in Havre

Havre, Montana – Northern Montana Health Care (NMHC) announced today the availability of Axonics Therapy—a long-lasting and clinically proven solution that provides symptom relief for patients suffering with overactive bladder, bowel incontinence, and urinary retention. Today, millions of people worldwide suffer from these chronic and debilitating symptoms.

The Axonics Therapy works by providing gentle electrical stimulation (sacral neuromodulation) to the nerves that control the bladder and bowel, restoring normal communication and resulting in an improvement in symptoms.

The Axonics System offers a long-lived miniaturized neurostimulator that is approximately the size of a quarter. The rechargeable device is implanted into the pelvic area during a minimally invasive, outpatient procedure. It is qualified to last 15 or more years in the body eliminating the need for repeat surgeries over the patient’s lifetime. Until today, the only other product available required replacement surgery every four years due to battery depletion and removal of the implanted device if an MRI was required. Patients are provided with a discreet easy to use Remote Control that can be used to manage their therapy.

Benefits of Axonics Therapy

• Clinically proven to help people regain urinary and bowel control

• 90% of implanted patients achieved clinically significant improvements

• Designed to provide patients with long-lasting relief

• Allows patients to undergo Full-Body MRI safely without having to explant the device

• High patient satisfaction at 6 months

• 93% of patients were satisfied with their therapy

Axonics, based in Irvine, Calif., has developed and is commercializing novel implantable Sacral Neuromodulation System (SNM) devices for patients with urinary and bowel dysfunction. These conditions are caused by a miscommunication between the bladder and the brain and significantly impacts quality of life. Overactive bladder affects an estimated 87 million adults in the U.S. and Europe. Another estimated 40 million adults are reported to suffer from fecal incontinence/accidental bowel leakage. SNM therapy has been employed to reduce symptoms and restore pelvic floor function for the past two decades. Reimbursement coverage is well established in the U.S. and Europe. The Axonics System is the first rechargeable SNM system approved for sale in the world, and the first to gain full-body MRI conditional labeling. For more information, visit the Company’s website at

“With its easy-to-charge battery, Axonics Therapy has an expected 15 year life in the body. Stimulation is automatically adjusted without human intervention, providing for consistent therapy while at the same time reducing patient fuss,” states Margo Muniz, MD, OB/GYN Provider at NMHC. “Pelvic floor conditions are more common than hypertension, depression, or diabetes. One in three adult women have hypertension; one in twenty adult women have depression; one in ten adult women have diabetes; and, more than one in two adult women suffer from pelvic floor dysfunction. Being able to offer this assistance for bladder and stool leakage here in Havre is important to us.”

More information can be found at Appointments may be booked with Dr. Muniz by calling (406) 265-5408.

Privacy Preferences
When you visit our website, it may store information through your browser from specific services, usually in form of cookies. Here you can change your privacy preferences. Please note that blocking some types of cookies may impact your experience on our website and the services we offer.